ARS Pharmaceuticals, Inc.

ARS Pharma to Report Third Quarter 2026 Financial Results

ARS Pharmaceuticals will host a conference call and webcast on Thursday, November 5, 2026, at 1:30 p.m. PT / 4:30 p.m. ET to review its third quarter 2026 financial results. No financial figures, guidance, or business updates were included in this announcement — it is solely an earnings-date notice. The company's lead product is neffy (epinephrine nasal spray), the only needle-free epinephrine approved by the FDA and EMA; a webcast replay will be available for 30 days.

•4d ago

Lifshitz Law PLLC Announces Investigations of Replimune Group, Inc. (NASDAQ: REPL), Datavault AI Inc. (NASDAQ: DVLT), Blaize Holdings, Inc. (NASDAQ: BZAI), and ARS Pharmaceuticals (NASDAQ: SPRY)

Lifshitz Law PLLC announced it is investigating possible securities-law violations at Blaize Holdings (BZAI), Replimune, Datavault AI, and ARS Pharmaceuticals. The allegations against Blaize center on claims that it announced transactions with entities unequipped to conduct meaningful business to create an appearance of growth and improperly recognized revenue. This is a preliminary law-firm investigation solicitation, not a filed lawsuit or issuer disclosure; no court action, certified class, or settlement exists yet.

•5d ago